MDxHealth SA (MDXH)


+0.10 (+3.70%)
Symbol MDXH
Price $2.8
Beta 0.871
Volume Avg. 0.08M
Market Cap 80.597M
Shares () -
52 Week Range 2.47-8.51
1y Target Est -
DCF Unlevered MDXH DCF ->
DCF Levered MDXH LDCF ->
ROE -215.63% Strong Sell
ROA -35.97% Strong Sell
Operating Margin -
Debt / Equity 152.26% Buy
P/E -1.18 Sell
P/B 2.46 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest MDXH news

Mr. Michael K. McGarrity
Diagnostics & Research
NASDAQ Capital Market

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.